Cytokinetics Stock

Cytokinetics EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Cytokinetics (CYTK) as of Aug 17, 2026 is -11.11. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -14.61 — a change of -23.98% (higher).

EV/EBIT

-11.11

YoY

-23.98%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Cytokinetics is 2026 -11.11 . EV/EBIT (Enterprise Value to EBIT) of Cytokinetics was 2025 -14.61 . It decreases by -23.98% higher compared to the previous year.

The Cytokinetics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-3.68 base
Jan 1, 2020
-15.67 base
Jan 1, 2021
-20.57 base
Jan 1, 2022
-12.43 base
Jan 1, 2023
-16.70 base
Jan 1, 2024
-10.02 base
Jan 1, 2025
-10.66 base
Jan 1, 2026 (e)
-79.91 base
YEARPRICE-TO-EBIT
2026 est -79.91
2025 -10.66
2024 -10.02
2023 -16.70
2022 -12.43
2021 -20.57
2020 -15.67
2019 -3.68
2018 -2.25
2017 -2.24
2016 16.43
2015 -6.32
2014 -11.55
2013 -1.22
2012 -0.49
2011 -0.31
2010 -0.58
2009 1.41
2008 -0.51
2007 -0.84
2006 -1.17
Access this data via the Eulerpool API
Get Free API Key

Cytokinetics Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Cytokinetics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Cytokinetics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Cytokinetics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Cytokinetics grows earnings faster than its peers.

Cytokinetics Stock analysis

What does Cytokinetics do? Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytokinetics stock

EV/EBIT (Enterprise Value to EBIT) of Cytokinetics is -11.11 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Cytokinetics changed from -14.61 to -11.11, representing a -23.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Cytokinetics since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Cytokinetics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Cytokinetics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Cytokinetics